This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion of ...

The artificial-intelligence-powered drug designer Recursion signed on to a wide-ranging collaboration with Roche and its Genentech division. Starting with a hefty $150 million upfront payment, the ...

The artificial intelligence (AI) revolution continues to tout developing drugs faster and at lower cost, but are we there yet? On October 2nd, the FDA cleared an investigational new drug (IND) ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

BioWorld - Thursday, February 8, 2024 See today's BioWorld Home » Recursion lands $60M series B to fund AI-driven drug repurposing, pipeline development Upgrade your daily dose of biopharma and ...

Recursion Pharmaceuticals Inc. has synthesized molecular glue degraders acting as RBM39 degradation inducers reported to be useful for the treatment of renal cell carcinoma.

Shares of early-stage biotech stocks, including Biohaven (NYSE: BHVN), Recursion Pharmaceuticals (NASDAQ: RXRX), and CRISPR Therapeutics (NASDAQ: CRSP), plunged in March, with the stocks down 35.3%, ...